Description     Claims     Drawing  

WO03102105A   [0008] 
WO200811077A   [0012] 
WO2009106855A   [0012]  [0046]  [0055] 
WO2010058227A   [0012]  [0036]  [0045] 
WO2011036429A   [0012]  [0062]  [0065] 
WO2011148200A   [0012]  [0056]  [0061] 
WO2005063293A   [0013]  [0021]  [0028]  [0067]  [0068] 
WO2011134898A   [0014] 
WO2008110777A   [0035] 
GB1218676A   [0142] 
GB1218758A   [0142] 
GB1304694A   [0142] 

Design of Prodrugs   [0087] 
Methods in Enzymology   [0087] 
A Textbook of Drug Design and Development   [0087] 
Design and Applications of Prodrugs   [0087] 
Advanced Drug Delivery Reviews   [0087] 
Journal of Pharmaceutical Sciences   [0087] 
Chem. Pharm. Bull.   [0087] 
Pro-drugs as Novel Delivery Systems   [0087] 
Bioreversible Carriers in Drug Design   [0087] 
Remington, The Science and Practice of Pharmacy   [0089] 
Invest. Ophthalmol. Vis. Sci.   [0115]  [0116] 
Ocular risk factors for developing neovascular AMD in the fellow eyes of patients with unilateral neovascular AMD   [0141] 
Age-related macular degeneration and blindness due to neovascular maculopathy   [0141] 
Diseases of macula - diagnosis and management of choroidal neovascularization   [0141] 
Drug therapy: Age-related macular degeneration   [0141] 
Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: Results of a phase I clinical trial   [0141] 
Vascular-permeability factor vascular endothelial growth-factor, microvascular hyperpermeability, and angiogenesis   [0141] 
differential regulation of VEGF/VPF and basic FGF by hypoxia   [0141] 
Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization   [0141] 
Perspective - A role for local inflammation in the formation of drusen in the aging eye   [0141] 
Angiopoietin/Tek interactions regulate MMP-9 expression and retinal neovascularization   [0141] 
Vascular endothelial growth-factor is a secreted angiogenic mitogen   [0141] 
Human Muller cells express VEGF183, a novel spliced variant of vascular endothelial growth factor   [0141] 
The vascular endothelial growth-factor family - identification of a 4th molecular-species and characterization of alternative splicing of rna   [0141] 
Newly identified biologically active and proteolysis-resistant VEGF-A isoform VEGF111 is induced by genotoxic agents   [0141] 
Vascular endothelial growth-factor - a new member of the platelet-derived growth-factor gene family   [0141] 
Vascular endothelial growth factor (VEGF) and its receptors   [0141] 
VEGF(165)b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma   [0141] 
VEGF(165)b, an inhibitory vascular endothelial growth factor splice variant: Mechanism of action, in vivo effect on angiogenesis and endogenous protein expression   [0141] 
Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor   [0141] 
VEGF(165)b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy   [0141] 
Expression of VEGF(xxx)b, the inhibitory isoforms of VEGF, in malignant melanoma   [0141] 
Recombinant Human VEGF(165)b Inhibits Experimental Choroidal Neovascularization   [0141] 
VEGF-A(165)b Is Cytoprotective and Antiangiogenic in the Retina   [0141] 
VEGF inhibition study in ocular neovascularization-1 (VISION-1): Efficacy results from phase II/III Macugen (TM) (Pegaptanib sodium) clinical trials   [0141] 
Ranibizumab: Phase III clinical trial results   [0141] 
Ranibizumab versus verteporfin for neovascular age-related macular degeneration   [0141] 
Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study   [0141] 
Efficacy and Safety of Monthly versus Quarterly Ranibizumab Treatment in Neovascular Age-related Macular Degeneration: The EXCITE Study   [0141] 
The role of endothelin in the pathophysiology of glaucoma   [0141] 
Risks of intravitreous injection: A comprehensive review   [0141] 
Regulation of Vascular Endothelial Growth Factor (VEGF) Splicing from Pro-angiogenic to Anti-angiogenic Isoforms a novel therapeutic strategy for angiogenesis   [0141] 
WT1 Mutants Reveal SRPK1 to Be a Downstream Angiogenesis Target by Altering VEGF Splicing   [0141] 
Reversible phosphorylation differentially affects nuclear and cytoplasmic functons of splicing factor 2/alternative splicing factor   [0141] 
Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors   [0141] 
Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema   [0141] 
Utilization of host SR protein kinases and RNA-splicing machinery during viral replication   [0141] 
A Human Neutralizing Antibody Specific to Ang-2 Inhibits Ocular Angiogenesis   [0141] 
Processive phosphorylation of alternative splicing factor/splicing factor 2   [0141] 
Mass spectrometric and kinetic analysis of ASF/SF2 phosphorylation by SRPK1 and Clk/Sty   [0141] 
Interplay between SRPK and Clk/Sty kinases in phosphorylation of the splicing factor ASF/SF2 is regulated by a docking motif in ASF/SF2   [0141] 
The evolution of alternative splicing exons in vascular endothelial growth factor A   [0141] 
VEGFA Family Isoforms Regulate Spermatogonial Stem Cell Homeostasis in Vivo   [0141] 
Expression of pro- and anti-angiogenic isoforms of VEGF in the mouse model of oxygen-induced retinopathy   [0141] 
Do Anti-Angiogenic VEGF (VEGFxxxb) Isoforms Exist? A Cautionary Tale   [0141] 
The balance of proangiogenic and antiangiogenic VEGFA isoforms regulate follicle development   [0141] 
VEGF(164)-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization   [0141] 
Drug delivery for posterior segment eye disease   [0141] 
Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors - Generation of receptor-selective VEGF variants by site-directed mutagenesis   [0141] 
Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms   [0141] 
SRPK1 Inhibition Modulates VEGF Splicing to Reduce Pathological Neovascularization in a Rat Model of Retinopathy of Prematurity   [0141] 
Topical Antiangiogenic SRPK1 Inhibitors Reduce Choroidal Neovascularization in Rodent Models of Exudative AMD   [0141]